Skip to main content
. 2019 Mar 5;8(5):e011112. doi: 10.1161/JAHA.118.011112

Figure 1.

Figure 1

Enrollment of patients with liver cirrhosis and nonvalvular atrial fibrillation. From June 1, 2012, to December 31, 2016, a total of 171, 535, and 732 NVAF patients with liver cirrhosis taking apixaban, dabigatran, and rivaroxaban and 990 patients taking warfarin were enrolled in the study. AF indicates atrial fibrillation; NOAC, non–vitamin K antagonist oral anticoagulant.